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African-American patients with end-stage renal disease have
historically lower hemoglobin concentrations and higher
requirements of erythropoiesis-stimulating agent (ESA).
While disparities in health-care access may partially explain
these findings, the role of variant hemoglobin, such as sickle
trait, has not been investigated. To clarify this, we evaluated
154 African-American patients receiving in-center
hemodialysis with available hemoglobin phenotyping. The
primary exposure was any abnormal hemoglobin variant and
the primary outcome of higher-dose ESA was defined as a
dose of 6500 or more units per treatment. Logistic regression
assessed the association between variant hemoglobin and
higher-dose ESA. Covariates included age, gender, diabetes,
iron parameters, intravenous iron dose, parathyroid hormone,
albumin, phosphorus, body mass index, vascular access type,
hospitalization/missed treatments, smoking status, alcohol
abuse, and gastrointestinal bleeding. Of 33 patients with
variant hemoglobin, 24 had HbAS and 9 had HbAC. Univariate
odds of higher-dose ESA among those with hemoglobin
variants were twice that of those with the normal HbAA
phenotype (odds ratio 2.05). In multivariate models, the
likelihood of higher-dose ESA had an odds ratio of 3.31
and the nature of this relationship did not change in Poisson
regression or sensitivity analyses. Hence, our findings may
explain, in part, the difference in ESA dosing between
Caucasians and African-Americans with end-stage renal
disease but await further study.
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Historically, African-American patients with end-stage renal
disease (ESRD) have had lower hemoglobin concentrations
at the start of dialysis when compared with other racial or
ethnic groups.1 The difference in hemoglobin persists into
the first year of renal replacement therapy despite similar
treatment protocols.1 Furthermore, observational data show
that African-American patients receiving chronic hemo-
dialysis (X90 days) require larger doses of erythropoiesis-
stimulating agents (ESAs) to achieve a similar level of
hemoglobin after adjustment for other modifying factors.2
African-Americans receive B12% more ESA than white
patients despite lower rates of hospitalization and catheter
use.2 Proposed explanations for this observation have
focused on disparities in access to predialysis care among
African-Americans,2 although these seem insufficient to
explain the persistence of higher ESA requirements through-
out dialysis care. An alternative or additional possibility is
that lower hemoglobin levels and higher ESA dosing may
be reflective of an underlying hemoglobinopathy.2 Further,
potential modifiers to ESA therapy may have relevance to
the planned bundling of ESRD payment that presently does
not include race/ethnicity nor hemoglobin variants in its
case-mix adjustment.3
Recently, we reported a high prevalence of heterozy-
gosity for hemoglobin S (HbAS) and hemoglobin C (HbAC)
in a group of African-Americans with ESRD receiving
renal replacement therapy.4 Although typically described as
a benign carrier state, individuals with either HbAS or
HbAC may experience clinical complications due to
changes to red-cell rigidity under situations of stress5–9 that
could lead to low-grade sickling and hemolysis. Specula-
tively, such changes could occur during the hemodialysis
procedure.
We therefore postulated that patients with these hemo-
globinopathies receiving hemodialysis would require
higher doses of ESAs. We examined the association of
these variant hemoglobins with ESA dosing in a group of
or ig ina l a r t i c l e http://www.kidney-international.org
& 2011 International Society of Nephrology
Received 11 June 2010; revised 24 April 2011; accepted 1 June 2011;
published online 17 August 2011
Correspondence: Vimal K. Derebail, Division of Nephrology and Hyper-
tension, Department of Medicine, UNC Kidney Center, University of North
Carolina at Chapel Hill, CB # 7155, Chapel Hill, North Carolina 27599, USA.
E-mail: vimal_derebail@med.unc.edu
992 Kidney International (2011) 80, 992–999
African-American patients receiving regular outpatient in-
center hemodialysis.
RESULTS
Of the 154 patients included in our analysis with at least 20
treatments over the 3-month study period, 33 had abnormal
hemoglobin phenotypes. Of these, 24 had sickle-cell trait or
HbAS and 9 had HbAC trait. Patients among all hemoglobin
phenotypes were similar in age (Table 1). Sex was distributed
similarly in all groups. Mean achieved hemoglobin was also
similar between those with normal and variant hemoglobin
phenotype. Patients with variant hemoglobin had received a
larger median dose of erythropoietin, particularly those with
HbAC trait—although not statistically significant; however,
iron dosing per treatment was similar. Median dialysis
vintage was notably greater in patients with hemoglobin
variants (P¼ 0.007). The average number of treatments
over the 3-month period was not significantly different
among all groups, although those with the normal hemo-
globin phenotype had a tendency to miss more treatments.
No statistically significant differences were noted in ade-
quacy (Kt/V), serum albumin, or iron saturation (Table 1).
Ferritin was not different when all hemoglobin variants were
viewed collectively, but did appear to be somewhat greater
among HbAS patients and slightly less among HbAC
patients. Although patients with variant hemoglobin tended
to have higher intact parathyroid hormone levels, largely
driven by the HbAS patients, these differences were not
statistically significant.
The frequencies of alcohol abuse, smoking, and history of
gastrointestinal bleeding (GI bleed) were similar between
patients with normal and variant hemoglobin. About two-
thirds of all patients were diabetic.
From our population of potential African-American
hemodialysis patients, 17 patients with o20 treatments were
not included, all of whom had normal hemoglobin
phenotypes. Five received no treatments over the study
period and had received a transplant, transferred, or expired.
The remaining 12 patients were predominantly male (10 of
12) and somewhat older (mean age 68.4 years) than the
included normal hemoglobin phenotype population.
These excluded patients had median ESA dose of 4937.43
U/treatment (interquartile range (IQR) 3107.1, 16062.5)
and lower average hemoglobin (10.4mg/dl, s.d. 1.6mg/dl).
Table 1 | Baseline characteristics of study population by hemoglobin phenotype
Normal hemoglobin
(HbAA; n=121)
Any variant hemoglobina
(n=33)
Sickle cell trait
(HbAS; n=24)
Hemoglobin C trait
(HbAC; n=9)
Age (years) 59.5 (13.9) 59.6 (13.8) 59.4 (12.9) 60.1 (16.8)
Sex
Male 61 (50.4%) 17 (51.5%) 13 (54.2%) 4 (44.4%)
Female 60 (49.6%) 16 (48.5%) 11 (45.8%) 5 (55.6%)
Body mass index (kg/m2)b 27.7 (23.4, 33.2) 27.1 (23.3, 31.8) 26.1 (23.1, 30.7) 28.9 (24.0, 33.2)
Hemoglobin (mg/dl) 11.8 (0.9) 12.0 (1.0) 12.0 (0.9) 12.2 (1.4)
Erythropoietin dose/treatment (units)b 3684.2 (1955, 6756.4) 4897.4 (2425, 8230.8) 4475.6 (2232.5, 8092) 7092.1 (2980, 8230.8)
Intravenous iron dose/treatment (mg)b 12.5 (0, 19.1) 12.8 (0, 16.0) 12.5 (0, 15.9) 12.9 (12.1,17.5)
Interdialytic weight gain (kg)b 2.60 (1.90, 3.20) 2.80 (2.30, 3.70) 2.55 (2.30, 3.45) 3.50 (2.40, 4.40)
Number of treatmentsb 39 (37, 40) 39 (38, 40) 39 (38, 40) 38 (32, 40)
Missed treatments (% of prescribed)b 0 (0, 5.3) 0 (0, 2.6) 0 (0, 2.5) 0 (0, 5)
Days hospitalized/weekc 0.17 (0.35) 0.05 (0.17) 0.05 (0.18) 0.08 (0.16)
Dialysis vintage (years)b 3.3 (1.7, 6.0) 6.1 (2.5, 8.7) 6.2 (2.9, 9.3) 5.8 (2.1, 6.8)
Kt/V 1.52 (0.33) 1.51 (0.27) 1.47 (0.16) 1.64 (0.43)
Albumin (mg/dl) 3.90 (0.32) 3.96 (0.34) 3.96 (0.34) 3.94 (0.36)
Ferritin (ng/ml) 723.5 (273.3) 787.6 (277.3) 834.1 (298.3) 663.3 (167.0)
Iron saturation (%) 32.1 (7.6) 31.8 (8.2) 31.2 (8.9) 33.2 (6.1)
Phosphorus (mg/dl) 5.40 (1.34) 5.36 (1.63) 5.40 (1.62) 5.23 (1.74)
iPTH (pg/ml)b 340 (240.8, 547.7) 393.3 (250.8, 622.7) 451.6 (269.3, 714.2) 342.8 (169.0, 475.9)
Vascular access
Arteriovenous fistula 48 (39.7%) 20 (60.6%) 14 (58.3%) 6 (66.7%)
Arteriovenous graft 44 (36.4%) 8 (24.2%) 5 (20.8%) 3 (33.3%)
Indwelling catheter 39 (24.0%) 5 (15.2%) 5 (20.8%) 0
Diabetes 74 (61.2%) 22 (66.7%) 16 (66.7%) 6 (66.7%)
History of smoking 19 (15.7%) 5 (15.2%) 2 (8.3%) 3 (33.3%)
History of alcohol abuse 11 (9.1%) 2 (6.1%) 2 (8.3%) 0
History of GI bleed 14 (11.6%) 3 (9.1%) 1 (4.2%) 2 (22.2%)
Abbreviations: GI bleed, gastrointestinal bleeding; iPTH, intact parathyroid hormone.
aIncludes HbAS and HbAC.
bMedian (IQR).
cWeek defined as three dialysis treatments (all patients assigned to thrice weekly dialysis).
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Data for several covariates were missing in up to 50% of
these observations.
Higher-dose ESA
Of the 121 patients with normal hemoglobin, 32 (26.5%)
were found to require higher-dose ESA as compared with
14 (42.4%) of the 33 patients with abnormal hemo-
globin variants. Patients requiring higher-dose ESA (Table 2)
had a lower achieved hemoglobin (P¼ 0.0002), lower
albumin (P¼ 0.004), lower iron saturation (0.001), higher
iron dose per treatment (0.001), more missed treatments
(P¼ 0.008), more hospitalizations (P¼ 0.007), and a higher
frequency of history of GI bleed (P¼ 0.05). A trend for
more common catheter use was noted among those with
higher-dose ESA; however, this was not statistically signifi-
cant. No other major differences were noted between the two
dosing groups.
In univariate analysis, the odds of higher-dose ESA
(defined as ESA dose X6500 U/treatment) among those
with hemoglobin variants were twice that of those with the
normal HbAA phenotype (Table 3). In multivariate models,
the association strengthened further, reaching statistical
significance. The fully adjusted model incorporated all
identified potential confounders (dialysis vintage, percent
of missed treatments, dialysis unit, serum albumin, iron
saturation, iron dose, vascular access type, history of GI
bleed, ferritin, intact parathyroid hormone, iron saturation,
and Kt/V). Individuals with hemoglobin variants had three
times the likelihood of higher-dose ESA than individuals with
HbAA (odds ratio (OR) 3.31, 95% CI 1.20–9.11). The
simplified model generated from backward elimination
and change-in-estimate testing adjusted for missed treat-
ments, dialysis access, and albumin produced similar results
with OR 3.02 (95% CI 1.26–7.25).
Poisson regression modeling, a more conservative method
of effect-size estimation, still revealed higher-dose ESA to be
nearly twice as likely among those with variant hemoglobin
than HbAA in fully adjusted and simplified models, with an
incident rate ratio of 1.94 (95% CI 1.16–3.25) and 2.03 (95%
CI 1.24–3.31), respectively (Table 3).
Sensitivity analyses
Using alternative definitions for higher-dose ESA in the
same fully adjusted multivariate logistic regression model,
we noted a slightly larger effect size at 7000 U/treatment
(Table 4) among those with variant hemoglobin. Although
variant hemoglobin was still associated with higher odds
of higher-dose ESA at definitions of 8000 U/treatment and
greater, our effect estimates were substantially smaller
and did not reach statistical significance. In addition,
further sensitivity analyses defining higher-dose ESA as a
weight-based measure, X100 U/kg/treatment, demonstrated
effects similar to that of our per-treatment definition—OR
1.9 (0.81–4.43) in univariate analysis (Table 4). When
adjusted as in our fully adjusted model, the association
also strengthened (OR 2.67, 95% CI 0.93–7.66), and in our
simplified model reached statistical significance (OR¼ 2.74,
95% CI 1.08–6.91).
We compared the 60 Caucasian patients from the same
dialysis units with similar inclusion criteria (X20 treatments
over the study period). No difference was discernable in ESA
dosing between Caucasian and African-American patients
with normal hemoglobin variants—median ESA dose 3959.2
Table 2 | Baseline characteristics of study population by need
for higher-dose ESA
ESA o6500
units/treatment
(n=108)
ESA X6500
units/treatment
(n=46)
Abnormal
hemoglobina
19 (17.6%) 14 (30.4%)
Age (years) 60.3 (13.2) 57.7 (15.3)
Sex
Male 55 (50.9%) 23 (50%)
Female 53 (49.1%) 23 (50%)
Body mass index
(kg/m2)b
27.9 (24.0, 33.3) 26.0 (22.0, 30.7)
Hemoglobin (mg/dl) 12.1 (0.9) 11.4 (0.9)
Erythropoietin dose/
treatment (units)b
2677.9
(1511.3, 4051.9)
10522.6
(8230.8, 14851.4)
Intravenous iron
dose/treatment
(mg)b
9.5 (0, 16.6) 16 .0 (10.6, 23.6)
Interdialytic weight
gain (kg)b
2.54 (1.90, 3.20) 2.60 (2.20, 3.5)
Number of
treatmentsb
39 (38, 40) 38 (28, 39)
Missed treatments
(% of prescribed)b
0 (0, 2.6) 2.5 (0, 16.2)
Days hospitalized/
weekb,c
0.09 (0.25) 0.27 (0.44)
Dialysis vintage
(years)b
3.8 (1.6, 7.0) 4.0 (2.1, 6.1)
Kt/V 1.50 (0.28) 1.56 (0.39)
Albumin (mg/dl) 3.96 (0.29) 3.80 (0.38)
Ferritin (ng/ml) 743.7 (274.1) 722 (278.0)
Iron saturation (%) 33.3 (7.4) 29.0 (7.6)
Phosphorus (mg/dl) 5.4 (1.3) 5.3 (1.6)
iPTH (pg/ml)b 347.7
(223.1, 547.7)
338.5
(261.0, 580.7)
Vascular access
Arteriovenous
fistula
51 (47.2%) 17 (37.0%)
Arteriovenous
graft
38 (35.2%) 14 (30.4%)
Indwelling
catheter
19 (17.6%) 15 (32.6%)
Diabetes 68 (63.0%) 28 (60.9%)
History of smoking 16 (14.8%) 8 (17.4%)
History of alcohol
abuse
8 (7.4%) 5 (10.9%)
History of GI bleed 8 (7.4%) 9 (19.6%)
Abbreviations: ESA, erythropoiesis-stimulating agent; GI bleed, gastrointestinal
bleeding; HbAC, hemoglobin C trait; HbAS, hemoglobin S trait; iPTH, intact
parathyroid hormone.
aIncludes HbAS and HbAC.
bMedian (IQR).
cWeek defined as three dialysis treatments (all patients assigned to thrice weekly
dialysis).
994 Kidney International (2011) 80, 992–999
or ig ina l a r t i c l e VK Derebail et al.: Variant hemoglobin and ESA dosing
(IQR 1982.1, 7738.5) and 3684.2 (IQR 1955, 6756.4),
respectively. As noted earlier, those African-Americans with
abnormal hemoglobin variants did have a higher median ESA
dose, 4897.4 (IQR 2425, 8230.8), although this was not
statistically significant (P¼ 0.6).
DISCUSSION
We found that variants of hemoglobin were significantly
associated with the dosing of ESA in this group of 154
African-American patients receiving hemodialysis. Those
individuals with an abnormal hemoglobin phenotype were
more likely to receive a higher dose of ESA, suggesting a
relative resistance to ESA. Sensitivity analyses, using varying
definitions of higher-dose ESA, revealed this association to be
robust. Our findings associating variant hemoglobin and
higher ESA dose raise questions regarding mechanism and
concerns about possible implications.
Several possible explanations exist for our observed
association. The mutations leading to hemoglobin S and C
both produce a structurally abnormal b-globin chain.
Precipitation of these chains occurs when the red blood
cell is exposed to conditions of stress ultimately leading
to increased rigidity of the cells.5–9 During a hemodialysis
session, red blood cells flow through an extracorporeal circuit
that is exposed to environmental stressors (low temperature
and low partial pressure of oxygen) potentially leading
to increased destruction of red blood cells and a shortened
half-life. Although we do not have measures of low-grade
red-cell destruction in the current cohort, measurement of
indices such as serum bilirubin, lactate dehydrogenase, and
haptoglobin could be instructive in future studies.
An alternative mechanism for relative ESA resistance may
be chronic inflammation. Patients with sickle-cell disease
(HbSS) have demonstrated inflammatory changes including
elevations in C-reactive protein and interleukin-6.10,11
A similar, albeit muted, process could occur in patients with
a single allele (or heterozygous sickle hemoglobin, HbAS).
Inflammation has been suggested to impair both iron
utilization and erythropoiesis.12–15 Numerous studies have
shown in the ESRD population that indices of active
inflammation, including C-reactive protein, have been
associated with ESA resistance.12,16,17 The presence of variant
hemoglobin would have to induce inflammatory responses
beyond those already experienced in hemodialysis. Finally,
antibodies to erythropoietin may contribute to an impaired
ESA response. Such antibodies have been reported in patients
with b-thalassemia and sickle/b(þ )-thalassemia,18 but may
not be common among ESRD patients.19 Future studies
should investigate the prevalence of such antibodies in ESRD
patients in relation to their hemoglobin phenotype.
Although requiring additional confirmation, the findings
of our study may have important implications. Exposure to
relatively high doses of ESA in the ESRD population has
raised safety concerns. The Normal Hematocrit Cardiac Trial,
a landmark study, demonstrated that normalizing hemo-
globin in ESRD patients was associated with increasing
mortality.20 Recent studies in patients with CKD also
suggested higher cardiovascular events and stroke with
higher levels of hemoglobin (and concurrently, higher doses
Table 3 | Association of variant hemoglobin and higher-dose ESAa
Univariate analysis Multivariate analysisb Simplified analysisc
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Logistic regression
Variant Hgb 2.05 (0.92–4.56) 0.08 3.31 (1.20–9.11) 0.02 3.02 (1.26–7.25) 0.01
IRR (95% CI) P-value IRR (95% CI) P-value IRR (95% CI) P-value
Poisson regression
Variant Hgb 1.60 (0.98–2.64) 0.06 1.94 (1.16–3.25) 0.01 2.03 (1.24–3.31) 0.005
Abbreviations: CI, confidence interval; ESA, erythropoiesis-stimulating agent; HbAS, hemoglobin S trait; OR, odds ratio.
aHemoglobin variants included sickle cell trait (HbAS) and hemoglobin C trait. Higher-dose erythropoiesis-stimulating agent defined as X6500 U/treatment (X19,500
U/week). Poisson regression used to more closely approximate risk ratio as odds ratio as determined by logistic regression likely overstates effect estimate, as outcome was
common (29.9%).
bMultivariate analysis from fully adjusted model—adjusted for percent of missed treatments, albumin, dialysis access, dialysis vintage, Kt/V, ferritin, iron saturation, intact
parathyroid hormone, dialysis unit, history of gastrointestinal bleeding, and iron dose per treatment.
cSimplified analysis or ‘final model’ derived from full model with removal of covariates by backward elimination via change in estimate testing—adjusted for percent of
missed treatments, albumin, and dialysis access.
Table 4 | Association of variant hemoglobin and alternative
definitions for higher-dose ESA
Variant hemoglobin
N OR (95% CI) P
Definition for higher-dose ESAa
X6000 U/treatment 14/33 2.96 (1.09–8.01) 0.03
X6500 U/treatment 14/33 3.31 (1.20–9.11) 0.02
X7000 U/treatment 13/33 4.15 (1.40–12.33) 0.01
X8000 U/treatment 9/33 2.43 (0.74–7.98) 0.1
X9000 U/treatment 7/33 1.92 (0.58–6.30) 0.3
X10,000 U/treatment 7/33 2.16 (0.65–7.21) 0.2
Weight-based definition for higher-dose ESA
X100 U/kg/treatmenta 11/33 2.67 (0.93–7.66) 0.07
X100 U/kg/treatmentb 11/33 2.74 (1.08–6.91) 0.03
Abbreviations: CI, confidence interval; ESA, erythropoiesis-stimulating agent;
OR, odds ratio.
aMultivariate analysis adjusted for percent of missed treatments, albumin, dialysis
access, dialysis vintage, Kt/V, ferritin, iron saturation, iPTH, dialysis unit, history of
gastrointestinal bleeding, and iron dose per treatment.
bAdjusted for percent of missed treatments, albumin, and dialysis access.
The bold row represents the primary outcome definition for higher-dose ESA used in
the initial analysis.
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of ESA).21–23 A secondary analysis of the Correction of
Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)
study suggested that these events occur more frequently in
those failing to reach their assigned target hemoglobin and
requiring higher doses of ESA.24 Although our two groups of
patients with and without variant hemoglobin achieved
similar hemoglobin, among those with higher-dose ESA in
either group, the achieved hemoglobin was lower. Future
studies should focus on determining the association between
mortality and higher-dose ESA and variant hemoglobin, and
should attempt to separate the effect, if any, of the underlying
hemoglobinopathy. At present, the Kidney Disease Outcome
Quality Initiative (KDOQI) recommends a target hemo-
globin of 11–12 g/dl among patients receiving dialysis
therapy, irrespective of the dose of ESA or intravenous
iron.25 With data arising that have associated morbidity with
ESA and higher hemoglobin targets, present practice has
shifted to a target range of 10–12 g/dl.26 Altering the goal
hemoglobin or setting a maximum dose of ESA may need to
be considered, particularly in populations more likely to
require higher-dose ESA, such as ours. The potential for a
lower target hemoglobin does have credence given the lower
hemoglobin concentration found among the general African-
American population compared with Caucasians and among
the chronic kidney disease population.27,28
In addition, our findings may have some relevance to
the proposed bundled-payment system instituted by Centers
for Medicare and Medicaid Services, which will include all
injectable medications, including ESA.29,30 In its current
iteration, the following patient and facility level character-
istics will be used to calculate payments—age, body mass
index, body surface area, and size of dialysis organization.
Race/ethnicity has not been incorporated as one of the
adjustment variables, although models using the planned
bundling system predict higher costs for African-American
patients, driven largely by higher costs for ESAs.31,32 Variant
hemoglobin, more common in this population, may partly
explain the higher ESA requirement. Notably, however, in our
study population, no difference was detectable between
African-Americans as a whole and Caucasians in median
dose of ESA, making it difficult to extrapolate our findings to
previous population studies. Our variant hemoglobin
African-American group did have higher median ESA than
Caucasians, albeit not statistically significant, suggesting the
potential role of these variants in the previous differences
noted. If the same target hemoglobin is presumed to be
appropriate in this population, including race, or more
specifically these variants, could provide further information
for revision of the bundling model. Alternatively, as above,
perhaps race-specific or hemoglobin variant-specific targets
may need to be devised.
Finally, although variant hemoglobins are unlikely to
affect overall mortality in ESRD, investigation of other
morbidities associated with variant hemoglobin may
be warranted in the ESRD population. Sickle-cell trait has
been demonstrated to be potentially prothrombotic.33,34
Recent evidence has associated ESAs and venous thrombo-
embolism.23,35 Such a relationship could theoretically place
ESRD patients with sickle-cell trait who are receiving ESAs at
an enhanced risk for venous thromboembolism and possibly
vascular access thrombosis, particularly in those patients with
synthetic arteriovenous grafts.36
The results of this study must be interpreted in the context
of its limitations. Because of the cross-sectional nature of
the study, we could not perform adjustment for varying levels
of hemoglobin, ESA, and other covariates that are likely to
change frequently. Ideally, a prospective study in a larger
population over a substantially longer period of time
would allow the use of time-dependent analyses and perhaps
even marginal structural models.37 In addition, our popula-
tion primarily had either sickle-cell trait or HbAS trait,
making the findings less applicable to other hemoglobino-
pathies. It is noteworthy that some patients with normal
hemoglobin may have had a false-negative diagnosis of
b-thalassemia trait, based on cutoffs for HbA2 and HbF
(43.1 and 42%, respectively; Laboratory Corporation
of America (LabCorp), Raritan, NJ). However, with an
assumption that b-thalassemia trait would also alter ESA
response,38 inclusion of these patients with those who had
normal hemoglobin would bias our effect toward the null. We
have also not been able to identify the role of a-thalassemia
in our population, which has been shown to mitigate some of
the effects of sickle-cell trait.39 However, if the proportion of
these variants in our patients is representative of the general
African-American ESRD population, our findings certainly
carry great relevance as at least 20% of African-American
patients could be affected.4
Our definition of higher-dose ESA is lower than the
typical dose noted in the Normal Hematocrit Cardiac Trial.20
The chosen cutoff point was based upon both the ESA dose
distribution in our population and the increase in mortality
noted in USRDS data.40 Furthermore, two other large studies
of patients receiving hemodialysis also noted an increase in
mortality associated with ESA doses X20,000 U/week,
similar to our definition of higher-dose ESA.41,42 Our
findings must also be interpreted in the context of the
proposed reductions to target hemoglobin that have been
suggested in the wake of the CHOIR and CREATE studies.
As a result, usage of ESAs is likely to be lower overall, and it
is not clear whether this would be proportional across all
patient populations. The differences we have noted for those
with variant hemoglobin may be blunted. Our sensitivity
analyses demonstrated an effect even with lower cutoff points
for our definition of higher-dose ESA, suggesting that our
observations may persist in the face of reduced ESA dosing.
Finally, data regarding the details of hospitalizations and
history of blood transfusions were not available for inclusion
in our analyses. We have been unable to correct more directly
for any degree of inflammation, as these markers are not
routinely obtained in these dialysis units.
In summary, we report a novel observation that, among
African-Americans, the presence of variant hemoglobin
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(HbAS and HbAC) increases the likelihood of higher-dose
ESA. Patients appear to have more than three times the odds
of receiving higher doses of erythropoiesis-stimulating agents
in order to maintain hemoglobin levels. Confirmation of
our findings is needed to explore whether the presence of
HbAS and HbAC affects patient safety and outcomes, as well
as practice patterns of dialysis clinics in the upcoming era
of bundling. Future studies, furthermore, should aim to
determine hemoglobin phenotype before initiation of ESA
therapy with prospective determination of administered ESA
dose and associated morbidity and mortality.
MATERIALS AND METHODS
Study population
Hemoglobin phenotyping was performed in June 2008 for African-
American ESRD patients receiving dialysis in four centers.
Ascertainment of race/ethnicity was determined by that recorded
in administrative data via the Medicare 2728 form. Of the 206
possible African-American patients identified, 188 completed
phenotyping; the others missed their scheduled visits for various
reasons including hospitalization, travel, or non-adherence. For the
purposes of consistency in management and data collections, we
chose to evaluate the population of in-center hemodialysis patients,
whose ESA dosing is determined by the same protocol (Supple-
mentary Figure S1 online) in all of the represented dialysis centers,
and excluded those receiving peritoneal dialysis (n¼ 16). All
patients were prescribed to three times weekly dialysis. Furthermore,
we required that patients in the study group received a minimum of
20 (or 50% of maximum) prescribed dialysis sessions over the 3-
month period to minimize potential bias that could be introduced
by patient illness and/or non-compliance. Only one patient was
noted to have b-thalassemia trait and was excluded to prevent
identity disclosure; 154 patients remained and comprised the final
study group. Using a cross-sectional approach, we reviewed
information over a 3-month period to minimize variability in
laboratory measurements and medication dosing. We also evaluated
characteristics of the 17 hemodialysis patients witho20 treatments,
who were not included, to ensure that their exclusion would not
profoundly affect our analyses. Review of all laboratory, demo-
graphic, and medical history data was approved by our institutional
review board.
Primary exposure
‘Variant hemoglobin’ represented our primary exposure, defined as
any hemoglobin phenotype containing a variant from normal adult
hemoglobin (HbAA). All hemoglobin phenotyping studies were
performed in June 2008 at a single laboratory site (LabCorp) using
high-pressure liquid chromatography. Sickle trait was defined by
high-pressure liquid chromatography as the presence of hemoglobin
A and S (HbAS), and hemoglobin C trait was defined as HbAC.
Patterns demonstrating elevated proportions of hemoglobin A2 and
hemoglobin F relative to hemoglobin A identified those with
b-thalassemia trait. We assessed the association of any variant
hemoglobin with the outcome, as well as each identified phenotype
individually.
Outcome
All patients were treated with the same intravenous ESA dosing
protocol to goal Hgb X11.1 o12.1mg/dl with percent dosing
adjustments made on the basis of measured hemoglobin level
(Supplementary Figure S1 online). We defined higher-dose ESA, our
primary outcome, as a dose of ESA equal to or exceeding 6500
U/treatment, equivalent to 19,500 U/week as all patients were
prescribed three treatments weekly. This value was chosen based
upon the distribution of ESA dosing in our study population, as well
as the dose above which mortality increased in both USRDS data
and secondary analysis of the CHOIR study.24,40 Delivered
erythropoietin doses were obtained as a summary measurement
over the specified time period. For each patient, we calculated the
per-treatment dose by dividing the total delivered dose by
the number of treatments received over the 3-month period. For
the purposes of sensitivity analysis, we also modeled alternative
definitions of higher-dose ESA using other cutoff points of ESA dose
per treatment, as well as a weight-based per-treatment definition for
higher-dose ESA. For this latter analysis, higher-dose ESA was
defined as a dose 4¼ 100 U/kg/treatment, representing greater
than the 75th percentile in the study population.
Covariates
Demographics and medical history maintained in administrative
databases at each dialysis unit were reviewed to extract information
on our additional covariates including age, sex, body mass index,
diabetes mellitus, history of GI bleed, tobacco abuse, and alcohol
abuse. Diabetes mellitus was defined either as the ascribed cause of
ESRD or as a comorbidity. Tobacco and alcohol abuse history were
recorded as dichotomous variables indicating presence or absence.
GI bleed was indicated as history of bleeding from any GI source.
Vintage of dialysis was calculated by subtracting the age of onset of
ESRD from the final date of the study. Iron dose per treatment was
calculated in a similar manner to erythropoietin per treatment. All
available laboratory studies were reviewed and averaged during the
3-month period for ferritin, iron saturation, parathyroid hormone,
serum albumin, serum phosphorus, and adequacy studies (Kt/V).
Interdialytic weight gain was taken as the difference between post-
weight and pre-weight. Information regarding type of vascular
access was extracted by review of administrative data sets
maintained by the vascular access program. The type of access was
coded as arteriovenous fistula, arteriovenous graft, or indwelling
hemodialysis catheter. In the event a catheter was used at any time in
the study period, patients were assigned to ‘catheter’ as their form of
access for analysis purposes as this has been reported to be the most
inflammatory of vascular access types.43 We also determined the
number of missed treatments, constructing a variable for a
proportion of missed treatments by dividing by the total of
prescribed treatments. We similarly evaluated days hospitalized over
the treatment period, producing a variable for days hospitalized per
treatment prescribed. Because hospitalization days and missed
treatments were felt to represent redundant measurements
(s¼ 0.6, Po0.0001), we chose to adjust for missed treatments as
this variable captured both non-adherence and hospitalizations.
Statistical analyses
Following evaluation of skewness and kurtosis, we calculated
means for normally distributed continuous variables and report
medians and interquartile ranges for continuous variables not
normally distributed. Counts and percentages were determined for
all categorical variables.
Prevalence ORs were obtained using univariate and multivariate
logistic regression. Logistic regression was also used to assess the
relationship between hemoglobin phenotype and higher-dose ESA.
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The association of any variant hemoglobin with the outcome was
assessed as a group and within each identified phenotype.
Because higher-dose ESA, as defined in our study, was not a rare
outcome (that is,410%), we also used Poisson regression modeling
to determine more conservative effect estimates where incidence rate
ratios serve as a less-inflated measure of risk than ORs.44 Two-sided
hypothesis testing with an a priori level of significance 0.05 was used
for all statistical inferences.
Potential covariates for inclusion in our models were derived from
previous studies of anemia in ESRD and potential mechanisms that
may influence anemia response. Measures considered as confounders
included age, sex, body mass index, diabetes mellitus, iron dosing,
ferritin, iron saturation, intact PTH, albumin, phosphorus, inter-
dialytic weight gain, vascular access type, history of smoking, alcohol
abuse, and GI bleed. Hemoglobin levels themselves were not included
in our covariate pool as we felt that this measurement lay upon the
causal pathway of our exposure. Within the included population,
missing data were present in fewer than 3% of observations and
constructed models used complete case analyses. Following univariate
analyses, we compared models with and without interaction terms
via likelihood ratio tests to assess for effect measure modification.
Using a conservative level of significance of 0.15 for these tests, we did
not identify any relevant interaction terms.
Because of the relatively small number of participants, we
attempted to create a model using a conservative number of
covariates. From our univariate analyses, we identified confounders
as those covariates that were either associated with the exposure or
with the outcome among the unexposed. Potential weak confound-
ers identified included dialysis vintage, percent of missed treatments,
dialysis unit, and serum albumin, iron saturation, iron dose,
vascular access type, and history of GI bleed. Hospitalization days
were also noted as a potential weak confounder, but were not
included in the model, as this information was felt to be included in
the missed treatment data. In addition, we chose to evaluate serum
ferritin, intact parathyroid hormone, iron saturation, and Kt/V in
our full model as these factors had been noted in earlier studies to be
associated with erythropoietin response.45–47
A fully adjusted model using all possible confounders was
constructed; we then created a simplified model removing
covariates, using backward elimination and change-in-estimate
testing. Only those variables the removal of which increased or
decreased the exposure estimate by X10% were retained in the
simplified model. Using the constructed logistic regression models,
we repeated these analyses using Poisson regression with the same
covariates. We also evaluated the two primary hemoglobin variants
separately (HbAS vs. HbAC) in univariate analysis. For the purpose
of sensitivity analyses, we used alternative definitions of higher-dose
ESA including a per-kg dose of ESA, substituting these for our
primary outcome in our fully adjusted logistic regression model. To
comment upon the racial difference in ESA dosing in our chosen
dialysis clinics, we also compared median dose of ESA for the
African-American patients with 60 Caucasian in-center hemodi-
alysis patients from the same four clinics. These patients represented
all of the Caucasians receiving treatment at the time of hemoglobin
phenotyping and who met the criteria of having missed fewer than
20 treatments over the study period. All were verified to have normal
hemoglobin phenotypes. All statistical analyses were performed
using Stata 10.1 (ref. 48).
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